47
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Oridonin-loaded poly(ε-caprolactone)–poly(ethylene oxide)–poly(ε-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma

, , , , , , , & show all
Pages 479-485 | Received 31 Jan 2008, Accepted 02 Apr 2008, Published online: 08 Oct 2008
 

Abstract

The aim of the present study was to develop a polymeric delivery system for water-insoluble drug oridonin. Amphiphilic block copolymers, poly(ε-caprolactone)–poly(ethylene glycol)–poly (ε-caprolactone) (PCL–PEO–PCL), were synthesized by ring-opening polymerization of caprolactone initiated by the hydroxyl groups of poly(ethylene glycol)6000 (PEG-6000) with stannous octoate as catalyzer. Oridonin-loaded PCL–PEO–PCL copolymer nanoparticles (ORI–PCL–PEO–PCL–NPs) were prepared by the interfacial deposition method. The mean particle size of the drug-loaded nanoparticles was 97.5 nm and the zeta potential was − 25 mV. The entrapment efficiency and actual drug loading of the nanoparticles were 87.52% ± 1.86% and 8.63% ± 0.49%, respectively. The antitumor activity of ORI–PCL–PEO–PCL–NPs was evaluated by measuring changes in tumor volumes, tumor weights, and survival rates of mice with grafted hepatoma (H22). The results indicated that ORI–PCL–PEO–PCL–NPs prolonged the survival time of mice and exhibited higher therapeutic efficacy compared with free oridonin. Thus, ORI–PCL–PEO–PCL–NPs may be used as a promising delivery system for liver cancer treatment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.